08:01 AM EDT, 07/23/2025 (MT Newswires) -- Rakovina Therapeutics (RKV.V) on Wednesday announced "meaningful" progress in its AI-driven KT-5000AI program, which is developing certain ATR inhibitors that are designed to disrupt the DNA damage response pathway in cancer cells.

Through its collaboration with Variational AI, Rakovina evaluated a large number of potential molecular structures. The most promising candidates are being prioritized for further characterization and potential development, a statement said.

"The progress we're seeing in the KT-5000AI program highlights the advantage of combining artificial intelligence with modern drug design," said Dr. Mads Daugaard, Rakovina president and chief scientific officer. "We're particularly encouraged by the number of active compounds emerging from the first wave of screening and look forward to advancing the most promising candidates through further evaluation and development."